Stock Evaluator: Endovia Health Sciences, Inc. (EDVA)
Endovia Health Sciences, Inc. EDVA
$0.17
0.00
0.29%
October 29, 2026 12:49:31 PM
EST
Volume: 91,556
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
AMEX | DELAYED PRICE
| SECTOR | INDUSTRY |
| Consumer Staples | Beverages |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Endovia Health Sciences, Inc. develops a diversified cannabinoid health sciences platform that translates science into regulated therapies and trusted health and wellness products for people and animals in Ireland, United Kingdom, Australia, and Latin America. Its product includes CannEpil a pharmaceutical-grade cannabinoid formulation comprising cannabidiol and tetrahydrocannabinol isolates in an oral liquid solution. Endovia Health Sciences, Inc. formerly known as Splash Beverage Group, Inc. The company is based in Fort Lauderdale, Florida.
Financial Summary
| Share Statistics | EDVA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.1 | $8,053.7 | 1% |
|
| Shares Out (Mil) | 3.1 | 187.7 | 11% |
|
| Institutional Ownership | 97.4% | 50.0% | 73% |
|
| Float (Mil) | 5.6 | 173.2 | 13% |
|
| Beta | -1.09 | 0.47 | 1% |
|
| Avg Daily Volume (000s) | 595 | 247 | 61% |
|
| Price Change (52-week) |
(97.7%) | 83.0% | 2% |
|
| Growth | EDVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 5.0% | na |
|
| Net Income (5yr) | 2.6% | 2.6% | 43% |
|
| EPS (5yr) | 28.0% | 6.2% | 79 |
|
| Dividends (5yr) | 0.0% | 4.5% | 0% |
|
| Cash Flow (5yr) | (30.0%) | (18.3%) | 19% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EDVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $5,799 | na |
|
| Net Income (TTM) (Mil) | ($17) | $360 | 25% |
|
| EPS (TTM) | ($13.601) | $0.400 | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | $946 | 25% |
|
| Net Cash Flow (TTM) (Mil) | na | $27 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $1,216 | 0% |
|
| Enterprise Value (Q1) (Mil) | $8 | $10,191 | 7% |
|
| Valuation | EDVA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.63 | na |
|
| P/E | na | 28.3 | na |
|
| Dividend Yield | na | 1.4% | na |
|
| PEG (5yr hist) | na | 2.6 | na |
|
| Ratios | EDVA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 44.9% | na |
|
| Net Margin | na | 7.3% | na |
|
| ROA | (148.3%) | 3.8% | 3% |
|
| ROE | 491.6% | 12.1% | 99% |
|
| Liabilities to Assets | na | 55.0% | na |
|
| F-Score | 2 | 6 | na |
|
Endovia Health Sciences, Inc. did not pass any screens on 10/28/2026.
